• Explore /
  • Poster
  • / Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC).

Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC).

Abstract Poster

Authors

Praful Ravi

Praful Ravi

Dana-Farber Cancer Institute, Boston, MA

Praful Ravi , Jiaming Huang , Wanling Xie , Bridget Whelpley , Emma Kelly , Bradley Alexander McGregor , Xiao X. Wei , Kerry L. Kilbridge , Srinivas Raghavan Viswanathan , Mary-Ellen Taplin , Christopher Sweeney , Martin T. King , Mai Anh Huynh , Atish Dipankar Choudhury

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 178)

DOI

10.1200/JCO.2023.41.6_suppl.178

Abstract #

178

Poster Bd #

F15

Abstract Disclosures

Similar Posters

First Author: Nicholas George Nickols

Poster

2023 ASCO Genitourinary Cancers Symposium

Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.

Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.

First Author: Heba Mohamed

First Author: Guillaume Grisay

First Author: Giulio Francolini